JCO global oncology · 2025
Global Access to Multiple Myeloma Therapies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Atallah Rawan, Shatnawi Yara, Ayoobkhan Md Fathima Shehnaz, Saif Md Saiful Islam, Naeem Menahil, Logan Emerson, Mushtaq Muhammad Umair, Rana Shabeeha, Mammadzadeh Aytaj, Hashmi Shahrukh K, Mohamed Benlazar, Desai Nihar, Carneiro Thiago Xavier, Popat Rakesh, McGuirk Joseph P, Atrash Shebli, Mahmoudjafari Zahra, Hammad Nada, Anwer Faiz, Ahmed Nausheen, Abdallah Al-Ola
Аннотация
PURPOSE: Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally.
METHODS: From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access.
RESULTS: Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.
CONCLUSION: Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.
METHODS: From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access.
RESULTS: Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.
CONCLUSION: Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.